Get the Stockscreener App
0.979
4.18%
0.0393
Unity Biotechnology Inc stock is traded at $0.979, with a volume of 11,876.
It is up +4.18% in the last 24 hours and down -46.36% over the past month.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$0.9397
Open:
$0.94
24h Volume:
11,876
Relative Volume:
0.06
Market Cap:
$16.36M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.2675
EPS:
-3.66
Net Cash Flow:
$-39.93M
1W Performance:
+0.93%
1M Performance:
-46.36%
6M Performance:
-30.07%
1Y Performance:
-33.85%
1-Day Range:
$0.94
$0.979
1-Week Range:
$0.9102
$1.0252
52-Week Range:
$0.8531
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Name
Unity Biotechnology Inc
Sector
Industry
Phone
(650) 416-1192
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Compare UBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.979 | 16.36M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.59 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.63 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
598.40 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.10 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.82 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-16-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-04-22 | Upgrade | ROTH Capital | Neutral → Buy |
| Nov-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Jun-28-21 | Upgrade | Citigroup | Sell → Buy |
| Jun-07-21 | Initiated | H.C. Wainwright | Buy |
| Feb-16-21 | Downgrade | Citigroup | Neutral → Sell |
| Aug-18-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-18-20 | Downgrade | Mizuho | Buy → Neutral |
| Aug-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-17-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-28-20 | Initiated | ROTH Capital | Buy |
| Dec-12-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Initiated | Mizuho | Buy |
| May-29-18 | Initiated | Citigroup | Buy |
| May-29-18 | Initiated | Goldman | Neutral |
| May-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Unity Biotechnology Inc Stock (UBX) Latest News
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock By Investing.com - Investing.com Australia
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com
Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView
HC Wainwright Has Pessimistic Outlook of UBX FY2026 Earnings - The AM Reporter
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga
Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - MarketScreener
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire
New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - Stock Titan
China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail
UNITY Biotechnology's UBX1325: A Game Changer for DME Treatment? - AInvest
UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq
UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire
Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - Stock Titan
Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail
3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail
This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail
Unity Biotechnology Reports 2024 Financial Results and Updates - MSN
Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times
Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World
HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World
Analysts Issue Forecasts for UBX Q1 Earnings - Defense World
Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World
UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com
Unity Biotechnology Inc Stock (UBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):